Abstract
The Swiss start-up Anaveon has raised about $35 million in its series A financing, led by the British life sciences investor Syncona and supported by the Novartis Venture Fund. The biotech is developing antibody agonists of the interleukin-2 receptor, with the goal of boosting the immune system’s ability to attack tumors in combination with other cancer therapies. Anaveon was founded in 2017 by IL-2 expert Onur Boyman, from the University of Zurich, and Andreas Katopodis, a former R&D director at Novartis.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
